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SUMMARY
Background
Recent innovations in gastrointestinal endoscopy have changed our traditional
approach to diagnosis and therapy in patients with inflammatory bowel dis-
eases (IBD). While traditionally used dye-based chromoendoscopy (DBC) tech-
niques suffer from several limitations that reduce their utility in daily routine
practice, newer ‘dye-less’ chromoendoscopy (DLC) techniques offer a great
potential to overcome most of these limitations.
Aim
To review available optical and digital chromoendoscopy techniques, by criti-
cally discussing their potential for diagnostic and surveillance colonoscopy in
patients with IBD.
Methods
A literature search on the use of dye-less and dye-based chromoendoscopy in
IBD patients was performed.
Results
In long-standing IBD, DBC improves detection of dysplasia (diagnostic odds
ratio = 17.5, 95% CI = 1.2–247.1) as well as prediction of inflammatory disease
activity and extent of disease compared with standard video-colonoscopy. Nar-
row band imaging (NBI) shows no improvement in dysplasia detection rates
compared with white-light endoscopy and DBC (P = 0.6). Moreover, NBI
results in a suboptimal differentiation of dysplastic from nondysplastic lesions.
No data regarding digital DLC techniques (i.e. FICE, i-scan) for dysplasia
detection in IBD are yet available. Both NBI and i-scan are superior to white-
light endoscopy in assessing the activity and extent of colorectal IBD.
Conclusions
Although the potential benefits of newer optical and digital dye-less chromo-
endoscopy techniques over traditionally used DBC are substantial, only DBC
can currently be recommended to improve dysplasia detection in long-standing
IBD. In contrast, DLC has the potential to quantify disease activity and
mucosal healing in IBD.
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INTRODUCTION
Chronic inflammation in inflammatory bowel diseases
(IBD) represents a major risk factor for the development
of colitis-associated cancer (CAC).1–3 In 2001, a large
meta-analysis assessed a pooled cumulative CAC inci-
dence of 2% at 10 years, 8% at 20 years and 18% after
30 years of disease.2 Unlike sporadic colorectal cancer,
the growing pattern of neoplastic tissue in IBD is often
flat, multifocal and anaplastic.4–7 At present, diagnosis of
dysplasia is the most reliable biomarker of malignancy,
being present in 70% of CAC.8 Based on these findings,
colonoscopic surveillance is strongly recommended by
national and international guidelines starting 8–10 years
after the onset of symptoms and every 1–2 years after
that in extensive colitis.9–12 Surveillance is aimed at early
detection of nonpolypoid (formerly known as ‘flat
lesions’) and early dysplastic lesions and includes four
random biopsies every 10 cm plus targeted sampling of
macroscopically suspicious lesions. However, this biopsy
protocol has failed to clearly demonstrate a significant
gain in mortality rates and cost-effectiveness, as signifi-
cant lesions may be overlooked according to their non-
polypoid appearance.1, 13–19 In addition, recent data have
shown that most gastroenterologists do not follow the
biopsy protocol, as it is a time- and cost-expensive
approach.20–25
To improve patient outcome, dye-based chromoendos-
copy (DBC) has been introduced more than one decade
ago, enabling the detection of significantly more dysplas-
tic lesions in long-standing IBD. In addition, DBC
allowed for an improved diagnosis of disease severity
and extent.15, 26–34 In this context, it has been estimated
that methylene blue-aided chromoendoscopy yields a
2.2-fold increase in dysplasia detection rate, particularly
due to the enhanced detection of nonpolypoid
lesions.15, 34, 35 Similar results were shown with the use
of indigo carmine.30, 33 A recent meta-analysis of six
randomised controlled trials demonstrated a pooled sen-
sitivity, specificity and diagnostic odds ratio of 83.3%
(95% CI = 35.9–99.6%), 91.3% (95% CI = 43.8–100%)
and 17.5 (95% CI = 1.2–247.1), respectively, for dyspla-
sia detection in long-standing ulcerative colitis (UC) by
using DBC compared with standard video-colonoscopy.36
Based on these results, DBC has already been included
in most national and international guidelines to improve
standard surveillance protocols in highly specialised cen-
tres.9–12 However, DBC has some potential limitations
hampering its feasibility in daily routine clinical
practice.37, 38 First, there are additional costs for dye
spraying and operator training. Furthermore, it is a
time-consuming procedure and the dye does not always
coat the surface evenly (Figure 1). Finally, the dye does
not provide a detailed evaluation of the subepithelial
capillary network, which is an important feature in the
diagnosis of gastrointestinal neoplasia and disease activ-
ity.37, 39
In the attempt to overcome most of these limitations,
recent advances in endoscopic imaging have been imple-
mented into daily routine practice (Table 1). Newer
dye-less chromoendoscopy (DLC) techniques allow for a
detailed examination of both the mucosal surface and
the mucosal vascular pattern (MVP) morphology by just
pushing a button on the handle of the endoscope,
thereby enabling high-contrast imaging of the mucosal
surface in real time without the use of special equipment.
These newer DLC techniques are divided into: (i) optical
chromoendoscopy and (ii) digital chromoendoscopy
(Table 2).
(a) (b)
Figure 1 | Methylene blue-aided chromoendoscopy yields an improved characterisation of subtle mucosal changes (a).
One disadvantage of the technique is the often inhomogeneous staining pattern, as the dye does not always coat the
whole surface evenly (b).
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In this review, we will focus and critically discuss the
potential of advanced endoscopic imaging using DLC for
diagnosis and surveillance in patients with IBD.
OPTICAL DLC
High-definition (HD) video endoscopes use white light
from a xenon source for illumination and capture the
reflected light by means of a charge-coupled device chip,
which is integrated into the distal tip of an endoscope.
The spectral composition of the reflected light depends
on the emission spectrum of the light source and the
features of the tissue (e.g. inflammatory, dysplastic). The
depth of penetration into the mucosa depends on the
light wavelength: it is superficial for blue band, deep for
red and intermediate for green (range of penetration:
0.15–0.30 mm).40 Haemoglobin streaming into the MVP
absorbs the greatest amount of visible light, with a prin-
cipal peak in the blue part of the spectrum (415 nm).
Optical chromoendoscopy is based on optical lenses
integrated within the light source of the endoscope,
thereby narrowing the bandwidth of spectral transmit-
tance. The two systems currently available for optical
DLC are Narrow Band Imaging (NBI; Olympus, Tokyo,
Japan) and Compound Band Imaging (CBI; Aohua,
Shanghai, China). By pushing a button on the handle of
the endoscope, optical DLC provides higher image con-
trast (i.e. ratio of density or brightness between a pattern
and its background) and allows visualisation of the
superficial capillary networks and of subepithelial ves-
sels.40–44 Multiple studies have shown that optical DLC
could enhance the detection of subtle irregularities and
allows for characterisation of the MVP (Figure 2). Muto
et al. have recently reviewed a detailed description of
NBI.41 No scientific data are currently available on the
recently introduced CBI.
DIGITAL DLC
Digital DLC is based on digital post-processing of the
endoscopic images in real time from the video processor
instead of narrowing the light by the use of optical fil-
ters.39, 45 Currently, two digital DLC techniques are avail-
able, including (i) Fujinon Intelligent Color Enhancement
(FICE; Fujifilm, Tokyo, Japan) and (ii) i-scan (Pentax,
Tokyo, Japan). Both techniques are enabled by pushing a
button on the handle of the endoscope, thereby recon-
structing virtual images in real time.
While FICE has no standardised settings, a recent
international consensus recommended uniform settings
Table 1 | Potential advantages of dye-less
chromoendoscopy in comparison to dye-based
chromoendoscopy
Enhancement of mucosal vascular pattern
Handiness: evenly staining just pushing a button
Time: no additional time consumption
Safety: no allergic reaction or potential DNA damage
Skill: swift learning curve
Table 2 | Summary of currently available dye-less
chromoendoscopy techniques
Technology Brand Company Specifications
Optical DLC NBI Olympus Evis Exera II & III
CBI Aohua AQ-100
Digital DLC i-scan Pentax EPKi, EPKi-5000, EPKi-7000
FICE Fujifilm EPX-4400
NBI, narrow band imaging; CBI, compound band imaging; FICE,
Fuji intelligent colour enhancement.
(a) (b)
Figure 2 | High-definition endoscopy with narrow band imaging (NBI) (a) and dual-focus NBI (b) in a patient with a
Mayo ulcerative colitis endoscopic score of 1. NBI improves visualisation of the mucosal vascular pattern.
Dual-focus NBI with 80-fold optical magnification yields an accurate assessment of subtle mucosal changes.
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for i-scan (Figure 3). The main advantage of this
approach is that it allows better comparability between
different studies. This was previously only possible for
studies evaluating optical chromoendoscopy techniques.
In particular, i-scan processes the reflected light using
three different algorithms: surface enhancement (SE),
contrast enhancement (CE) and tone enhancement (TE).
SE augments luminance, edges contrast and allows a
detailed evaluation of the mucosal surface and lesion
borders. With CE, areas lower in luminance intensity
compared with surrounding pixels are recognised and
refined upon a slight suppression of red and green fre-
quencies; as a result, relatively dark areas are stained in a
slightly bluish colour, thereby enhancing the presence of
vessels, to apply a more detailed topography of subtle
irregularities and of the MVP. TE divides the reflected
white light into three colours (red, green and blue) and
performs a selective modification of each frequency fol-
lowed by image reconstruction in real time. The three
i-scan settings are recommended as follows: (i) i-scan 1
for detection of lesions. This algorithm uses only SE to
refine imaging of subtle surface abnormalities without
altering the brightness of the endoscopic picture. (ii)
i-scan 2 mode was established for characterisation of
lesions. The algorithm combines SE and TE, thereby
enhancing minute mucosal changes and vessel structures.
(iii) i-scan 3 adds CE to the endoscopic image (in addi-
tion to SE and TE) and is recommended for demarcation
of lesions, as it digitally adds blue colour to darker edges
within the endoscopic image.
The FICE system is similarly based on a computed
spectral estimation technology that digitally processes the
white-light endoscopic image in real time. Nevertheless,
standardised settings are currently missing, thereby ham-
pering the use of FICE in daily routine practice and
comparison of different studies.
DLC IN IBD – DETECTION OF NEOPLASIA
Detection of colorectal dysplasia in IBD is of paramount
importance, being the most reliable biomarker of
CAC.8, 46 Progression from chronic inflammation to
cancer was previously supposed to strictly follow a step-
by-step sequence from low-grade dysplasia, to high-grade
dysplasia and cancer.47 Recent evidence suggests a shift
of this paradigm. Driven by different pathways, invasive
cancer seems to have the potential to develop de novo
and from low-grade dysplasia without the intermediate
stage of high-grade dysplasia.48 Accordingly, low-grade
dysplasia is considered the definitive interventional point
at which the prophylactic colectomy for CAC in chronic
UC should be discussed.49 In addition, IBD-related neo-
plasia may arise in nonpolypoid mucosa with normal
endoscopic appearance or may arise as dysplasia-associ-
ated lesion or mass (DALM).50 For an optimised ther-
apy, these lesions have to be distinguished from those
arising from sporadic adenomas in healthy or noncolitis
mucosa (adenoma-like mass; ALM).51 In this context,
advanced endoscopic imaging using DLC has been stud-
ied to increase accuracy and effectiveness of current
surveillance programmes in IBD (Table 3).
Recently, a cross-sectional pilot study including 46
patients with long-standing UC evaluated the positive
predictive value of conventional white-light endoscopy
and NBI for diagnosis of early colorectal neoplasia.52
(a) (b) (c)
NAME
ID
Dr
Facility
NAME
ID
Dr
Facility
NAME
ID
Dr
Facility
i-scan 1 i-scan 2
15/Mrz/2013AGE AGE
15:04:50
15/Mrz/2013
15:05:03
i-scan 3
AGE 15/Mrz/2013
15:04:41
Figure 3 | High-definition endoscopy with digital chromoendoscopy using different i-scan settings. Panel a shows
i-scan 1 mode, which is used for detection of lesions. This algorithm uses surface enhancement (SE) to refine imaging
of subtle surface abnormalities without altering the brightness of the endoscopic picture. i-scan 2 mode (b) combines
SE and tone enhancement (TE) for characterisation of lesions and enhancement of subtle mucosal changes and
vascular structures. Panel c highlights i-scan 3 mode, which adds contrast enhancement and is recommended for
demarcation of lesions, as it digitally adds blue colour to darker edges within the endoscopic image.
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Table 3 | Summary of the main studies addressing the use of dye-less chromoendoscopy in IBD
Main studies addressing the use of DLC in IBD
Author-
Journal-Year
No. of
patients
Study design
and setting
Endoscopic
techniques Indication Endoscopic efficacy Statistics
Evidence
provided
Dekker,
Endoscopy,
2007
42 Crossover
trial with
randomised
order in UC
surveillance
NBI vs.
Standard
WLE
Surveillance –
dysplasia
detection
True-positive lesions:
9 with NBI and
12 with WLE
False-positive lesions:
43 with NBI and
16 with WLE
Missed dysplastic
lesions: three with
NBI (two HGD, one
not reported), four
with WLE (two LGD,
one HGD, one
intramucosal cancer)
P = 0.672
P = 0.015
Comparable
dysplasia
detection
rate between
NBI and
standard
WLE. NBI
leads to
detection of
more false-
positive
lesions than
WLE
van den
Broek,
Endoscopy,
2011
48 Crossover
trial with
randomised
order and
matching
lesion in UC
surveillance
NBI + HD
vs. WLE +
HD
Surveillance –
dysplasia
detection
True-positive lesions:
13 with NBI and 11
with HD-WLE
Missed dysplastic
lesions (all LGD):
three with NBI, five
with HD-WLE
P = 0.727 Comparable
dysplasia
detection
rate between
NBI and
HD-WLE
Surveillance –
Dysplasia
differentiation
Sensitivity, specificity
and overall accuracy
of the Kudo
classification by NBI
in differentiating
neoplastic from
nonneoplastic lesions
were 76%, 66% and
67% respectively
Not
applicable
Unsatisfactory
NBI accuracy
differentiating
neoplastic
from
nonneoplastic
mucosa
Ignjatovic,
Am J
Gastro-
enterol,
2012
112 Parallel
randomised
trial in UC
surveillance
NBI + HD
vs. WLE
+ HD
Surveillance –
Dysplasia
detection
True-positive lesions:
five with NBI and
seven with HD-WLE
False-positive lesions:
12 with NBI and 4
with HD-WLE
P = 0.57
P = 0.06
Comparable
dysplasia
detection
rate between
NBI and
HD-WLE
van den
Broek,
Gut,
2008
50 Crossover
trial with
randomised
order in UC
surveillance
NBI + HD
vs. AFI +
HD
Surveillance –
Dysplasia
differentiation
Sensitivity, specificity
and overall accuracy
of the Kudo
classification by NBI
in differentiating
neoplastic from
nonneoplastic lesions
were 75%, 81% and
80% respectively
Not
applicable
Moderate NBI
accuracy
differentiating
neoplastic
from nonneo-
plastic mucosa
Pellise,
Gastrointest
Endosc,
2011
60 Crossover
trial with
randomised
order in IBD
surveillance
NBI + HD
vs. DBC
with Indigo
carmine
and WLE +
HD
Surveillance –
Dysplasia
detection
True-positive lesions:
10 with NBI and
12 with DBC
False-positive lesions:
126 with NBI and
196 with DBC
Missed dysplastic
lesions: 7/22 with
NBI and 3/22
with DBC
P = 0.644
P = 0.001
P = 0.200
Comparable
dysplasia
detection
rate between
NBI and DBC
with indigo
carmine. NBI
leads to
detection of
less false-
positive
lesions than
DBC
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Each protruding and nonpolypoid lesion was further
observed by using magnifying NBI colonoscopy. By
modifying the classification for ‘magnifying chromoscop-
ic findings’,53–56 the surface structure was classified into
three different patterns: (i) ‘honeycomb-like’, (ii) ‘villous’
and (iii) ‘tortuous’. Notably, the last surface structure
was significantly related to dysplasia on histology (8%
compared to 0.4% in ‘honeycomb-like’ and villous pat-
terns. P = 0.003), meaning that the ‘tortuous’ pattern
revealed by NBI may be a clue for the identification of
colorectal neoplasia.52 Moreover, a recent crossover trial
randomised 42 patients with long-standing UC (defined
as pancolitis and disease duration of at least 8 years) and
compared dysplasia detection rates between standard
white-light endoscopy and NBI.57 Importantly, no statis-
tically significant differences in the detection rates of
dysplastic lesions were detected between NBI (nine
lesions) and standard white-light endoscopy (12 lesions)
according to a per-lesion analysis (P = 0.672).
A later study by the same group compared HD
white-light endoscopy with HD endoscopy with NBI in
48 patients with long-standing UC, but failed to reveal
any significant difference between both groups.58 NBI
detected 13 dysplastic lesions, while HD white-light
endoscopy detected 11 dysplastic lesions (P = 0.727).
Besides using a crossover design with matched lesions to
increase the statistical power, potential limitations of the
study have to be discussed: first, the biopsy protocol
Table 3 | (Continued)
Main studies addressing the use of DLC in IBD
Author-
Journal-Year
No. of
patients
Study design
and setting
Endoscopic
techniques Indication Endoscopic efficacy Statistics
Evidence
provided
Bisschops,
Endoscopy,
2012
108 Parallel
randomised
trial in UC
surveillance
NBI + HD
vs. DBC
with
methylene
blue and
WLE + HD
Surveillance –
Dysplasia
detection
True-positive lesions:
18 with NBI (of 112
raised polyps) and
26 with DBC (of
156 raised polyps)
Median withdrawal
time: 20 min for
NBI and 27 min
for DBC
P = 0.385
P = 0.003
Comparable
dysplasia
detection
rate between
NBI and DBC
with
methylene
blue. NBI
enables
faster
examination
than DBC
Kudo,
Endoscopy,
2009
30 Observational
trial in mild
or inactive
UC
NBI + HD Diagnosis –
Prediction
of microscopic
activity
Distorted mucosal
vascular pattern
with ‘obscure’
NBI appearance
correlates with
signs of microscopic
inflammation, such
as cell infiltration,
goblet cell depletion,
distorted crypts and
basal plasmacytosis
All P values
are equal
to 0.0001
NBI may
predict signs
of active
microscopic
inflammation
Neumann,
Inflamm
Bowel Dis,
2013
78 Parallel
randomised
trial in active
or inactive
IBD
i-scan + HD
vs. WLE +
HD
Diagnosis –
Prediction
of microscopic
activity
i-scan shows
better agreement
with histological
results compared
with HD-WLE,
assessing both
disease extent
(92% vs. 49%)
and disease
activity (90%
vs. 54%)
P = 0.001
P = 0.066
i-scan may
predict signs
of active
microscopic
inflammation,
thereby
refining the
assessment
of disease
extent and
severity
DLC, dye-less chromoendoscopy; DBC, dye-based chromoendoscopy; NBI, narrow band imaging; HD-WLE, high-definition white-
light endoscopy; AFI, auto-fluorescence imaging; UC, ulcerative colitis; LGD, low-grade dysplasia; HGD, high-grade dysplasia.
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applied during the first examination resulted in up to 44
(27%) small lesions, which were completely removed due
to their diminutive size (five low-grade and one high-
grade dysplasia). Second, biopsied lesions may have
become predictably smaller or changed their original
appearance, shrinking the power of a real comparison
between two different techniques. Nevertheless, the
results have recently been confirmed by a multicentre
trial including 112 patients with long-standing UC.59
According to the per-lesion analysis, the overall detection
rate of neoplastic lesions was again comparable between
the HD white-light and the NBI group (7 vs. 5;
P = 0.57).
Taken together, the results of the above-mentioned
studies suggest that NBI could not improve the detection
rate of colorectal dysplasia in IBD. No data regarding
the use of digital DLC techniques for dysplasia detection
in IBD are currently available.
Previous studies using DBC had shown that pan-chro-
moendoscopy with either methylene blue or indigo car-
mine has the potential to improve detection rates of
colorectal dysplasia in patients with long-standing
UC.15, 32–36, 60 To date, two studies have compared DLC
with DBC to evaluate dysplasia detection rates in IBD.
The first study by Pellise et al. used a crossover design
with randomised order (NBI vs. indigo carmine) of 60
clinically inactive colonic IBD patients 8 years after the
onset of symptoms.61 In the per-lesion analysis, NBI
showed a similar true-positive biopsy rate compared with
DBC (10 vs. 12, P = 0.644), but an inferior false-positive
biopsy rate (126 vs. 196, P = 0.001). Furthermore, NBI
clearly scored over indigo carmine-aided chromoendos-
copy in terms of a shorter withdrawal time (mean
15.7 min for NBI and 26.9 min for DBC, P < 0.01),
according to the fewer number of ‘suspicious lesions’
recognised and biopsied (136 with NBI and 208 with
DBC, P = 0.001). Nevertheless, when the rate of missed
neoplastic lesions was taken into account, the per-patient
analysis (6/13 with NBI and 2/13 with DBC, P = 0.2) and
the per-lesion analysis (7/22 with NBI and 3/22 with DBC,
P = 0.2) showed a slightly positive trend towards DBC.
The second study used a multicentre parallel rando-
mised design and included 108 patients with long-stand-
ing UC undergoing surveillance colonoscopy.62 The
preliminary study results revealed that methylene blue-
aided chromoendoscopy and NBI have a comparable
detection rate of true neoplastic lesions in endoscopically
detected, suspiciously elevated lesions. Eighteen of 112
raised polyps were detected with NBI and 26 of 156
raised polyps with DBC (P = 0.385). Furthermore, given
the shorter withdrawal time of DLC (median 20 min for
NBI and 27 min for DBC, P = 0.003) and the easier
applicability, the authors suggested that NBI might have
the potential to replace DBC for surveillance in IBD in
the future.
Besides the detection of pre-neoplastic and neoplastic
lesions in IBD, DLC was also evaluated for the charac-
terisation of colorectal lesions in IBD (Table 3). One
recent published study by van den Broek et al. reported
that, according to the Kudo classification, accuracy of
NBI for in vivo differentiation of neoplastic and nonneo-
plastic lesions in IBD was 67%.58 Another study by the
same group reported a moderate efficacy of NBI for pre-
diction of dysplasia in IBD (sensitivity 75%, specificity
81% and accuracy 80%).63 Taken together, these preli-
minary data did not support the use of NBI to predict
histology in IBD. In this context, the presence of slight
mucosal disease activity and tissue alterations, driven by
chronic inflammation, have to be discussed to explain
the relatively low impact of NBI for the characterisation
of dysplastic lesions in IBD.
ASSESSMENT OF MUCOSAL HEALING, DISEASE
ACTIVITY AND EXTENT
Looking beyond colorectal dysplasia detection and char-
acterisation, DLC has also been evaluated for diagnosis
of early inflammatory changes in IBD (Table 3). Emerg-
ing evidence suggests that mucosal healing is a key treat-
ment goal that predicts sustained clinical remission and
resection-free survival of IBD patients.64 Accordingly,
mucosal healing has become a pivotal prognostic para-
meter in the management of IBD, thus highlighting the
importance of endoscopy for monitoring of disease activ-
ity. It has been recognised that increased vascular density
and angiogenesis may play a crucial role in the patho-
genesis of IBD and could be closely related to disease
activity.65–74 Indeed, angiogenesis and MVP could repre-
sent the proof of earlier or residual mucosal activity in
spite of a deep clinical remission.75–80
In a pilot study based on 14 IBD patients, immuno-
histochemical staining with CD31 revealed a significant
increase in mucosal angiogenesis in NBI ‘positive areas’
(increased MVP intensity) in comparison to conven-
tional white-light endoscopy (P < 0.05).75 However,
based on a small sample size, the study demonstrated
the potential of NBI for in vivo imaging of intestinal
neoangiogenesis in IBD patients.75
Another pilot study evaluated small-bowel findings in
patients with Crohn’s disease by using double balloon
enteroscopy with FICE. Notably, FICE could not
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improve the detection or delineation of ulcers and ero-
sions due to Crohn’s disease.81 Nevertheless, the study
was designed to assess the application of FICE for differ-
ent small-bowel pathologies and included only three
Crohn’s disease patients. Moreover, active disease with
ulcers and wide erosions are commonly revealed by stan-
dard white-light endoscopy, thereby lowering space to
show any technological gain related to DLC.
In contrast, evaluating less severe markers of inflamma-
tion, Kudo et al. analysed the MVP in asymptomatic or
mildly active UC by using both HD white-light endoscopy
and NBI, while histology was defined as the golden stan-
dard.76 While HD white-light endoscopy was feasible to
detect the presence of a ‘distorted’ vascular pattern
(defined as either irregular or tortuous), NBI revealed a
more intense visualisation of vessel structures, thereby
enabling the distinction between ‘clear’ and ‘obscure’
MVP. Both acute and chronic signs of microscopic inflam-
mation were remarkably correlated with the ‘obscure’
MVP (P < 0.05), while only a minority among the chronic
signs of inflammation correlated with the ‘distorted and
clear’ MVP (P = 0.0007). Therefore, evaluation of the
MVP with NBI yielded a more precise determination of
acute microscopic inflammation in patients with quiescent
UC. The same group performed two additional studies,
confirming the strong correlation between NBI vascular
findings and histological clues of inflammation.77, 78
Reviewing these evidences, the authors distinguished the
‘distorted’ MVP observed in conventional colonoscopy
from two different NBI patterns: one defined as ‘clear’ and
the other one as ‘obscure’.79 Histopathological findings
such as inflammatory cell infiltration, goblet cell depletion,
distorted crypts and basal plasmacytosis were significantly
more often found in biopsy specimens from ‘obscure’
appearing areas under NBI. Accordingly, NBI has the
potential to predict histological severity in mild and inac-
tive disease stages.
These data have also been confirmed in a recent parallel
randomised trial evaluating i-scan for prediction of disease
severity and extent in patients with mild or inactive
IBD.80 In this study, 78 IBD patients were consecutively
and randomly enrolled to receive either HD white-light
endoscopy or HD endoscopy with i-scan. Average dura-
tion of the examination did not differ between two groups.
Comparing the endoscopic prediction of inflammatory
extent and activity with the histological results, i-scan
agreement scored 92% and 90%, respectively, while
HD white-light endoscopy scored for 49% and 54%
respectively. These differences were partially statistically
significant (P = 0.001 and P = 0.066 respectively).
Therefore, i-scan has the potential to improve the assess-
ment of mucosal disease severity and extent in patients
with IBD.
CONCLUSION AND FUTURE PERSPECTIVE
In the last decade, several endoscopy units have adopted
the use of optical and digital DLC techniques to improve
detection and characterisation rates of neoplastic lesions
and assessment of mucosal healing in patients with
long-standing IBD. These newer DLC techniques are
integrated into modern endoscopes and highlight the
mucosal and vascular pattern morphology in real time
by just pushing a button on the endoscope.
Despite an increasing, scientific and clinical, interest
in these DLC techniques, most studies have failed in
showing a significant benefit and improvement of DLC
in comparison to traditionally used DBC.
Studies based on surveillance of long-standing IBD
suggested that NBI could not improve dysplasia detec-
tion compared with white-light endoscopy.52, 57–59 On
the contrary, NBI showed an equivalent dysplasia detec-
tion rate compared with DBC with indigo carmine dye
spraying.61 Beyond that, studies on digital DLC tech-
niques for detection of neoplastic lesions in IBD are still
missing. Characterisation of colorectal lesions in IBD is
of paramount importance for subsequent therapy. In this
context, preliminary data have shown an insufficient
accuracy of NBI for characterisation of neoplastic from
nonneoplastic colorectal lesions in IBD, while no data
are available on the use of digital DLC for characterisa-
tion of colorectal lesion in IBD.58, 63 In addition, no data
are available on the effectiveness of DLC techniques for
in vivo diagnosis of DALM and ALM. The differential
diagnosis of these entities is therefore still based on clini-
cal and histological findings.51, 82, 83
In contrast, by using histology as the reference standard,
both NBI and i-scan have recently been shown to improve
diagnosis of activity and extent of the disease in patients
with IBD in comparison to white-light endoscopy. There-
fore, these techniques harbour the potential to predict his-
tological severity in mild and inactive disease stages and to
redefine the term of mucosal healing.75–80
Taken together, at present, evidence suggests that
DLC does not improve dysplasia detection rates over
DBC. Moreover, based on currently available data, DLC
techniques are not an adequate substitute for histology
in suspected IBD-associated dysplasia. Future develop-
ments should assess the use of DLC in detection of
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subtle inflammatory changes and mucosal angiogenesis
in IBD.
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